Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How many years does kadcyla's market exclusivity last?
Norcuron generic name?
Antiox mebendazole price?
Is allopurinol expensive?
Can i take anti histamine with statin?

Daridorexant synthesis quviviq?

See the DrugPatentWatch profile for Daridorexant

How is Daridorexant Synthesized?


The synthesis of daridorexant, the active pharmaceutical ingredient in Quviviq, involves a multi-step chemical process. While specific detailed synthetic routes are often proprietary, patent literature and scientific publications offer insights into potential pathways.

What are the Key Chemical Steps in Daridorexant Synthesis?


Daridorexant's chemical structure, 2-(5-chloro-1,3-benzodioxol-4-yl)-1-(2-(2-methoxyphenoxy)phenyl)ethanone, suggests that its synthesis would involve forming the benzodioxole ring, attaching the ethanone linker, and connecting the two aromatic systems. Typical synthetic strategies for molecules of this complexity often employ coupling reactions, functional group transformations, and protection/deprotection steps. For instance, building blocks containing the benzodioxole moiety and the substituted phenyl rings would likely be prepared separately and then joined together.

When Might Daridorexant Patents Expire?


The patent landscape for pharmaceuticals is complex, with various patents covering different aspects of a drug, including composition of matter, manufacturing processes, and methods of use. Information on specific patent expiry dates for daridorexant can be found through specialized databases. For example, DrugPatentWatch.com tracks patent information and exclusivity periods for many drugs [1].

Can Generic Versions of Daridorexant Be Developed?


The development of generic versions of daridorexant is contingent upon the expiry of relevant patents and regulatory approvals for generic drug applications. Once the primary patents protecting the active pharmaceutical ingredient and its use expire, and if bioequivalence is demonstrated, generic manufacturers may seek to market their versions.

What are the Regulatory Considerations for Daridorexant?


Daridorexant, marketed as Quviviq, is regulated by health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approval requires extensive clinical trials demonstrating safety and efficacy for its intended use, which is the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

What is the Mechanism of Action for Daridorexant?


Daridorexant acts as a dual orexin receptor antagonist. Orexin neuropeptides play a role in promoting wakefulness. By blocking the binding of orexin-A and orexin-B to their receptors (OX1R and OX2R), daridorexant reduces the stimulation of wakefulness and thereby facilitates sleep [2].

Sources:


1. DrugPatentWatch.com
2. https://www.fda.gov/media/159099/download



Other Questions About Daridorexant :

Daridorexant ema approval date european union quviviq insomnia? Daridorexant saudi arabia? Daridorexant synthesis patent steps? Idorsia daridorexant patent? Daridorexant synthesis steps iupac? Wo patent daridorexant synthesis example? Daridorexant synthesis patent scheme?

AI-Drug Label Prescribing Information Alignment Report

65
65%
Grade C

Partial

Partial Aligned

Patient Risk: Low

Summary

Matches the FDA-approved indication (adult insomnia with sleep onset and/or sleep maintenance difficulties) but includes several mechanism/biology and regulatory/approval process statements that are not supported by the provided label text and cannot be verified against the supplied excerpts.

Category Scores

Indication
100
Excellent

Accurate Statements

Daridorexant is the active pharmaceutical ingredient in Quviviq.
Section 11 DESCRIPTION: "QUVIVIQ contains daridorexant..."
Daridorexant is a dual orexin receptor antagonist.
Section 11 DESCRIPTION: "daridorexant, an orexin receptor antagonist" (the provided excerpt does not state "dual"; see unsupported/unspecified below)
Orexin neuropeptides promote wakefulness.
Not supported in the provided label excerpts.
Daridorexant blocks the binding of orexin-A and orexin-B to orexin receptors OX1R and OX2R.
Not supported in the provided label excerpts.
By reducing stimulation of wakefulness, daridorexant facilitates sleep.
Not supported in the provided label excerpts.
Daridorexant is regulated by health authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Not supported in the provided label excerpts.
Approval of daridorexant requires extensive clinical trials demonstrating safety and efficacy for its intended use.
Not supported in the provided label excerpts.
Daridorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Section 1 INDICATIONS AND USAGE: "indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance"

Unsupported Statements

Daridorexant is a dual orexin receptor antagonist.
The provided label excerpt states "orexin receptor antagonist" but does not specify "dual" or reference OX1R/OX2R.
Orexin neuropeptides promote wakefulness.
No such biological/mechanistic statement appears in the provided label excerpts.
Daridorexant blocks the binding of orexin-A and orexin-B to orexin receptors OX1R and OX2R.
The provided label excerpts do not mention orexin-A/orexin-B or OX1R/OX2R binding.
By reducing stimulation of wakefulness, daridorexant facilitates sleep.
The provided label excerpts do not describe this mechanistic causal pathway.
Daridorexant is regulated by health authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
No regulatory-status statement for FDA/EMA is present in the provided label excerpts.
Approval of daridorexant requires extensive clinical trials demonstrating safety and efficacy for its intended use.
No statements about approval requirements or trial extensiveness are present in the provided label excerpts.

Contradictions

Important Omissions

The label excerpt for indications specifies "adult patients"; the AI statement does not explicitly include "adult" (it says "insomnia characterized..." without age qualifier).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The only clearly label-supported claim provided is the insomnia indication description; other statements are mechanistic/regulatory/approval-process claims that are not supported by the supplied label excerpts but also do not directly alter dosing or contraindications in the provided response.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partial Aligned

Primary Issue
Multiple mechanism/regulatory/approval-process statements are not supported by the provided label excerpts; additionally, the age qualifier "adult" is omitted in the indication paraphrase.

Suggested Improvement
Limit claims to what is explicitly present in the provided label excerpts (e.g., orexin receptor antagonist and the adult insomnia indication); avoid specifying unquoted receptor binding details (OX1R/OX2R, orexin-A/orexin-B) and avoid regulatory/approval-process assertions not contained in the label text.

Drug Brand Mention Assessment

Branding Score
22
Visibility
31
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

acts as a dual orexin receptor antagonist

Core Claims
  • The synthesis of daridorexant involves a multi-step chemical process
  • The drug is marketed as Quviviq
  • Daridorexant acts as a dual orexin receptor antagonist
  • It blocks orexin-A and orexin-B binding to OX1R and OX2R
  • It is used for insomnia with difficulties with sleep onset and/or sleep maintenance
Differentiators
Pricing Perception: Not Mentioned